Abstract
Genetic polymorphism of the carcinogen metabolizing enzyme N -acetyl transferase 2 (NAT2) may influence susceptibility to bladder cancers related to smoking or to occupational exposure to arylamine carcinogens. This article reviews the results of 21 published case–control studies of NAT2 polymorphism and bladder-cancer risk, with a total of 2700 cases and 3426 controls. The published evidence suggests that NAT2 slow acetylator phenotype or genotype may be associated with a small increase in bladder cancer risk. However, given the possibility of selective publication of results from studies that found an excess risk, the current evidence is not sufficient to conclude that there is a real increase in risk. Only five of the 21 studies reported results separately for the effect of NAT2 on bladder cancer risk in smokers and non-smokers. Although the results suggest that the effect may be greater in smokers than in non-smokers, the possibility of publication bias makes these results difficult to interpret. There was insufficient evidence to assess the joint effect of NAT2 and occupational exposure to arylamines on bladder cancer risk. Even if estimates of the effect of NAT2 from published data are correct, studies with around 3000–5000 cases will be needed to confirm them. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bicho MP, Breitenfeld L, Carvalho AA and Manso CF (1988) Acetylation phenotypes in patients with bladder carcinoma. Ann Genet 31: 167–171
Brockmöller J, Cascorbi I, Kerb R and Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56: 3915–3925
Cartwright RA (1979) Genetic association with bladder cancer. BMJ 2: 798
Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E and Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842–845
Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K and Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57: 581–592
Case RA, Hosker ME, McDonald DB and Pearson JT (1954) Tumours of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. British Journal of Industrial Medicine 11: 75–104
Cox DR and Snell EJ (1989) Analysis of Binary Data, 60. Chapman and Hall: London
Cuzick J (1999) Interaction, subgroup analysis and sample size. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds), pp. 109–121, International Agency for Research on Cancer: Lyon
d'Errico A, Taioli E, Chen X and Vineis P (1996) Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1: 149–173
d'Errico A, Malats N, Vineis P and Boffetta P (1999) Review of studies of selected metabolic polymorphisms and cancer. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds), pp. 323–393, International Agency for Research on Cancer: Lyon
Dewan A, Chattopadhyay P and Kulkarni PK (1995) N-acetyltransferase activity – a susceptibility factor in human bladder carcinogenesis. Indian J Cancer 32: 15–19
Egger M, Schneider M and Davey Smith G (1998) Meta-analysis: Spurious precision? Meta-analysis of observational studies. BMJ 316: 140–144
Evans DAP, Eze LC and Whibley EJ (1983) The association of the slow acetylator phenotype with bladder cancer. J Med Genet 20: 330–333
Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL and Grewal R (1997) Human acetyltransferase polymorphisms. Mutat Res 376: 61–70
Hanke J and Krajewska B (1990) Acetylation phenotypes and bladder cancer. Journal of Occupational Medicine 32: 917–918
Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W and Ovenbeck R (1985) Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 11: 263–266
Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL and Meyer UA (1993) N-Acetylation phenotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 14: 675–678
Hein DW (1998) Acetylator phenotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37–66
Hirvonen A (1999) Polymorphic NATs and cancer predisposition. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds), pp. 251–270, International Agency for Research on Cancer: Lyon
Horai Y, Fujita K and Ishizaki T (1989) Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37: 581–587
Hwang S-J, Beaty TH, Liang K-L, Coresh J and Khoury MJ (1994) Minimum sample size estimation to detect gene-environment interaction in case-control designs. Am J Epidemiol 140: 1029–1037
Ishizu S, Hashida C, Hanaoka T, Maeda K and Ohishi Y (1995) N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. Jpn J Cancer Res 86: 1179–1181
Kaisary A, Smith P, Jaczq E, McAllister CB, Wilkinson GR, Ray WA and Branch RA (1987) Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488–5493
Kalo R, Estabrook R W and Cayen M N (eds) pp 449–506, Taylor and Francis: London
Kantor AF, Hartge P, Hoover RN and Fraumeni JF Jr (1985) Familial and environmental interactions in bladder cancer risk. Int J Cancer 35: 703–706
Karakaya AE, Cok I, Sardas S, Gogus O and Sardas OS (1986) N-Acetyltransferase phenotype of patients with bladder cancer. Human Toxicology 5: 333–335
Kiemeny LA, Moret NC, Witjes JA, Schoenberg MP and Tulinius H (1997) Familial transitional cell carcinoma among the population of Iceland. J Urol 157: 1649–1651
Knowles MA (1998) Molecular genetics of bladder cancer: pathways of development and progression. In: Cancer Surveys 31: Bladder Cancer, Oliver R TD and Coptcoat M J (eds), pp. 49–76, Imperial Cancer Research Fund-Cold Spring Harbour Laboratory Press: New York
Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D and Uson AC (1985) Hepatic acetylator phenotype in bladder cancer patients. Annals of Clinical Research 17: 96–99
Lee SW, Jang IJ, Shin SG, Lee KH, Yim DS, Kim SW, Oh SJ and Lee SH (1994) CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 9: 482–489
Le Marchand LL, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens A and Lau AF (1998) Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58: 4858–4863
Lin HJ, Han C-Y, Lin BK and Hardy S (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4: 125–134
Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE and Bryan GT (1979) N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71–79
Miller ME and Cosgriff JM (1983) Acetylator phenotype in human bladder cancer. J Urol 130: 65–66
Mommsen S, Barfod NM and Aagaard J (1985) N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 6: 199–201
Okkels H, Sigsgaard T, Wolf H and Autrup H (1997) Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225–231
Oxman AD and Guyatt GH (1992) A consumer's guide to subgroup analysis. Ann Intern Med 116: 79–84
Peluso M, Airoldi L, Armelle M, Martone T, Coda R, Malaveille C, Giacomelli G, Terrone C, Casetta G and Vineis P (1998) White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 7: 341–346
Probert JL, Persad RA, Greenwood RP, Gillatt DA and Smith PJB (1998) Epidemiology of transitional cell carcinoma of the bladder: profile of an urban population in the south-west of England. Br J Urol 82: 660–666
Risch A, Wallace DM, Bathers S and Sim E (1995) Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 4: 231–236
Roots I, Drakoulis N, Brockmöller J, Janicke I, Cuprunov M and Ritter J (1989) Hydroxylation and acetylation phenotypes as genetic risk factors in certain malignancies. In: Kato R, Estabrook R W and Cayen M N (eds)Xenobiotic Metabolism and Disposition, pp 499–506, Taylor and Francis: London
Rothman N, Garcia-Closas M, Stewart WT and Lubin J (1999) The impact of misclassification in case-control studies of gene-environment interactions. In: Metabolic Polymorphisms and Susceptibility to Cancer, Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds), pp. 89–96, International Agency for Research on Cancer: Lyon
Silverman DT, Morrison AS and Devesa SS (1996) Bladder cancer. In: Cancer Epidemiology and Prevention, Schottenfeld D and Fraumeni J F (eds), pp. 1156–1179, OUP: New York, Oxford
Smith CAD, Wadelius M, Gough AC, Harrison DJ, Wolf CR and Rane A (1997) A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34: 758–760
Sone M (1986) [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls]. [Japanese]. Hinyokika Kiyo 32: 1085–1092
Sorlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Borresen-Dale A-L and Montesano R (1998) Analysis of p53, p16 MTS1. p21WAF1and H-ras in archived bladder tumours from workers exposed to aromatic amines. Br J Cancer 77: 1573–1579
Su HJ, Guo YL, Lai M-D, Huang J-D, Cheng Y and Christiani DC (1998) The NAT2* slow genotype is associated with bladder cancer in Taiwanese, but not in the Black Foot Disease endemic area population. Pharmacogenetics 8: 187–190
Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL and Bell DA (1998) The role of N -acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction. Cancer Res 58: 3603–3610
Vatsis KP, Weber WW, Bell DA, Dupret J-M, Price Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T and Yamazoe Y (1995) Nomenclature for N-acetyltransferases. Pharmacogenetics 5: 1–17
Vineis P (1992) Epidemiological models of carcinogenesis: the example of bladder cancer. Cancer Epidemiol Biomarkers Prev 1: 149–153
Vineis P, Malats N, Lang M, d'Errico A, Caporaso N and Boffetta P (eds) (1999) Metabolic Polymorphisms and Susceptibility to Cancer. International Agency for Research on Cancer: Lyon
Whiteman DC, Parsons PG and Green A (1998) p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 77: 843–848
Woodhouse KW, Adams P, Clothier A, Mucklow J and Rawlins MD (1982) N-acetylation phenotype in bladder cancer. Human Toxicology 1: 443–445
Woolhouse NM, Qureshi MM, Bastaki SMA, Patel M, Abdulrazzaq Y and Bayoumi RAL (1997) Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 7: 73–82
Xie H-G, Xu Z-H, Ou-Yang D-S, Shu Y, Yang D-L, Wang J-S, Yan Z-D, Huang S-L, Wang W and Zhou H-H (1997) Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics 7: 503–514
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Green, J., Banks, E., Berrington, A. et al. N -acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene–environment interaction. Br J Cancer 83, 412–417 (2000). https://doi.org/10.1054/bjoc.2000.1265
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1265
Keywords
This article is cited by
-
Comparison of Bladder Carcinogens in the Urine of E-cigarette Users Versus Non E-cigarette Using Controls
Scientific Reports (2018)
-
Effect of NAT2 gene polymorphism on bladder cancer risk in Slovak population
Molecular Biology Reports (2011)
-
Epidemiology of urinary bladder cancer: from tumor development to patient’s death
World Journal of Urology (2007)
-
N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk
Oncogene (2006)
-
Tobacco use and cancer: an epidemiologic perspective for geneticists
Oncogene (2002)